Great investor presentation (again).
Interesting to note the parameters and subs aspired by our imminent breastcancer phase 1 complete data sets.
ORR >25%, and pCR>16% (11-22).
May be worth a re-visit to the 1b top line results for some (encouraging indeed).
Also, would like to know the progress of the ptx-100 orphan drug application.
As our CEO stated’ multiple shots at goal’.
Luck to all holders.
PTX Price at posting:
8.5¢ Sentiment: Buy Disclosure: Held
